

RECEIVED
CENTRAL FAX CENTER


JAN 12 2007

Application No.: 10/749,121
Applicants: Jeffrey O. Saunders et al.CLAIM AMENDMENTS

Please replace all prior versions and listing of claims with the amended claims as follows:

1-74. (canceled)

75. (new) A method of treating or preventing an SHP-2-mediated disease or condition in a patient selected from an autoimmune disease, a proliferative disease, or an angiogenic disorder comprising the step of administering to said patient a compound of formula (I-A):



or a pharmaceutically acceptable salt thereof, wherein:


Q is an optionally substituted group selected from C₁₋₈ aliphatic, C₆₋₁₀ aryl, heteroaryl having 5-10 ring atoms, and heterocyclyl having 3-10 ring atoms; and

X is selected from -CH₂-, -C(O)-, or -CF₂.

76. (new) The method according to claim 75, wherein Q is selected from C₆₋₁₀ aryl and 5-6 membered heterocyclyl.









77. (new) The method according to claim 75, wherein X is -CH₂-.

78. (new) The method according to claim 75, wherein said compound is selected from:



Application No.: 10/749,121
 Applicants: Jeffrey O. Saunders et al.

wherein

No.	-X-	-Q
I-3	-CH ₂ -	
I-5	-CH ₂ -	
I-8	-CH ₂ -	
I-9	-CH ₂ -	
I-10	-CH ₂ -	
I-11	-CH ₂ -	
I-12	-CH ₂ -	
I-13	-CH ₂ -	

79. (new) A method of treating or preventing an SHP-2-mediated disease or condition in a patient selected from an autoimmune disease, a proliferative disease, or an angiogenic disorder, in a patient comprising the step of administering to said patient a compound according to claim 78.

Application No.: 10/749,121
Applicants: Jeffrey O. Saunders et al.

80. (new) The method according to claim 79 wherein said method is used to treat or prevent an autoimmune disease selected from glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Graves disease, autoimmune gastritis, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, ulcerative colitis, Crohn's disease, psoriasis, or graft vs. host disease.

81. (new) The method according to claim 79 wherein said method is used to treat or prevent a proliferative disease selected from acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, and HTLV-1-mediated tumorigenesis.


82. (new) The method according to claim 79 wherein said method is used to treat or prevent an angiogenic disorder selected from solid tumors, ocular neovascularization, and infantile haemangiomas.

83. (new) The method according to claim 79 further comprising the step of administering to said patient an additional therapeutic agent.

84. (new) The method according to claim 79 wherein said additional therapeutic agent is selected from a chemotherapeutic agent, an anti-proliferative agent, or an anti-inflammatory agent.

85. (new) A method of inhibiting SHP-2-mediated activity in a biological sample comprising the step of contacting said biological sample with a compound of formula (I-A):

Application No.: 10/749,121
Applicants: Jeffrey O. Saunders et al.



or a pharmaceutically acceptable salt thereof, wherein:

Q is an optionally substituted group selected from C_{1-8} aliphatic, C_{6-10} aryl, heteroaryl having 5-10 ring atoms, and heterocyclyl having 3-10 ring atoms; and

X is selected from $-CH_2-$, $-C(O)-$, or $-CF_2$.

86. (new) A method of inhibiting SHP-2-mediated activity in a biological sample comprising the step of contacting said biological sample with a compound according to claim 78.